There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo versus sunitinib.

The R2-MTX and POR/ROM regimens achieved higher response rates than R-MTX but showed no statistical advantage in overall survival.

Models estimated patient’s lifetime risk of dying from nonmetastatic prostate cancer rather than other causes.

Positive associations seen for celiac disease, SLE, T1D with pancreatic, esophageal, colon, liver, and hepatobiliary cancers.

Researchers explored immunoglobulin replacement therapy patterns and the effect of serious infection in a real-world cohort of patients with CLL.

Researchers investigated the relationship between antiplatelet medication and the risk for liver fibrosis, PVT, and hepatocellular carcinoma.

UTUC has distinct molecular alterations, so bladder recurrences and treatment efficacy might differ from primary bladder carcinoma.

43.2 percent missed opportunity rate reported for germline genetic testing, risk-reducing surgery in those with affected first-degree relative.

Comparison of pre- and postintervention measures demonstrated that AI chatbots can effectively improve education and attitudes of patients with breast cancer.

Researchers sought to determine whether combination talquetamab and teclistamab would be a viable treatment option for patients with RRMM and EMD.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.